|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Combination Therapy With Sirolimus and Interleukin-2 Prevents Spontaneous and Recurrent Autoimmune Diabetes in NOD Mice
1 Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
2 Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
3 Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
Sirolimus is an immunosuppressant that inhibits interleukin (IL)-2 signaling of T-cell proliferation but not IL-2-induced T-cell apoptosis. Therefore, we hypothesized that administration of IL-2, together with sirolimus, might shift T-cell proliferation to apoptosis and prevent autoimmune destruction of islet ß-cells. We found that sirolimus and IL-2 therapy of female NOD mice, beginning at age 10 weeks, was synergistic in preventing diabetes development, and disease prevention continued for 13 weeks after stopping sirolimus and IL-2 therapy. Similarly, sirolimus and IL-2 were synergistic in protecting syngeneic islet grafts from recurrent autoimmune destruction after transplantation in diabetic NOD mice, and diabetes did not recur after stopping sirolimus and IL-2 combination therapy. Immunocytochemical examination of islet grafts revealed significantly decreased numbers of leukocytes together with increased apoptosis of these cells in mice treated with sirolimus and IL-2, whereas ß-cells were more numerous, and significantly fewer were apoptotic. In addition, Th1-type cells (
-interferon-positive and IL-2+) were decreased the most, and Th2-type cells (IL-4+ and IL-10+) and Th3-type cells (transforming growth factor-ß1+) were increased the most in islet grafts of sirolimus and IL-2-treated mice. We conclude that 1) combination therapy with sirolimus and IL-2 is synergistic in protecting islet ß-cells from autoimmune destruction; 2) diabetes prevention continues after withdrawal of therapy; and 3) the mechanism of protection involves a shift from Th1- to Th2- and Th3-type cytokine-producing cells, possibly due to deletion of autoreactive Th1 cells.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Strauss, T. L. Whiteside, A. Knights, C. Bergmann, A. Knuth, and A. Zippelius Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin J. Immunol., January 1, 2007; 178(1): 320 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Battaglia, A. Stabilini, E. Draghici, B. Migliavacca, S. Gregori, E. Bonifacio, and M.-G. Roncarolo Induction of Tolerance in Type 1 Diabetes via Both CD4+CD25+ T Regulatory Cells and T Regulatory Type 1 Cells Diabetes, June 1, 2006; 55(6): 1571 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Battaglia, A. Stabilini, E. Draghici, S. Gregori, C. Mocchetti, E. Bonifacio, and M.-G. Roncarolo Rapamycin and Interleukin-10 Treatment Induces T Regulatory Type 1 Cells That Mediate Antigen-Specific Transplantation Tolerance Diabetes, January 1, 2006; 55(1): 40 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hui, N. Khoury, X. Zhao, L. Balkir, E. D'Amico, A. Bullotta, E. D. Nguyen, A. Gambotto, and R. Perfetti Adenovirus-Mediated XIAP Gene Transfer Reverses the Negative Effects of Immunosuppressive Drugs on Insulin Secretion and Cell Viability of Isolated Human Islets Diabetes, February 1, 2005; 54(2): 424 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pearson, P. Weiser, T. G. Markees, D. V. Serreze, L. S. Wicker, L. B. Peterson, A.-M. Cumisky, L. D. Shultz, J. P. Mordes, A. A. Rossini, et al. Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice Is Controlled by Allelic Variants of Idd3 Diabetes, August 1, 2004; 53(8): 1972 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Suarez-Pinzon, J. G. Mabley, R. Power, C. Szabo, and A. Rabinovitch Poly (ADP-Ribose) Polymerase Inhibition Prevents Spontaneous and Recurrent Autoimmune Diabetes in NOD Mice by Inducing Apoptosis of Islet-Infiltrating Leukocytes Diabetes, July 1, 2003; 52(7): 1683 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pearson, T. G. Markees, L. S. Wicker, D. V. Serreze, L. B. Peterson, J. P. Mordes, A. A. Rossini, and D. L. Greiner NOD Congenic Mice Genetically Protected From Autoimmune Diabetes Remain Resistant to Transplantation Tolerance Induction Diabetes, February 1, 2003; 52(2): 321 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujitani and A. Trifilieff In Vivo and In Vitro Effects of SAR 943, a Rapamycin Analogue, on Airway Inflammation and Remodeling Am. J. Respir. Crit. Care Med., January 15, 2003; 167(2): 193 - 198. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |